Tributyrin
Based on 1 publication(s) in Google Scholar
Tributyrin (Glyceryl tributyrate), a neutral short-chain fatty acid triglyceride, is a stable and rapidly absorbed proagent of Butyric Acid. Tributyrin diffuses through biological membranes and is metabolized by intracellular lipases, releasing effective butyrate directly into the cell in vivo. Tributyrin has potent antiproliferative, proapoptotic and differentiation-inducing effects.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.0%
- CAS No.: 60-01-5
- Formule: C15H26O6
- Masse moléculaire:302.36
-
Stockage:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Tributyrin
MoreVoir tous les produits spécifiques à Isoform TNF Receptor
More
Activité biologique
|
IL-1β |
Tributyrin (0.8 mM, 48 hours) induces significant growth inhibition in PC-3 cells[3]. Tributyrin (0.5-5 mM, 48 hours) causes G1 cell cycle arrest in LNCaP cells[3]. Tributyrin (0.1-5 mM, 48 hours) induces higher apoptosis rates in PC-3 and TSU-PR1 cells[3]. Tributyrin (1-5 mM, 48 hours) induces prostate-specific antigen expression in LNCaP cells, suggesting its differentiation effect[3]. Tributyrin (1 mM, 24 hours) directly inhibits the production of TNF-α and IL-1β in RAW 264.7 cells under LPS stimulation[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:LNCaP, PC-3, TSU-PR1 cells (human prostate cancer)
-
Concentration:0.1-5 mM
-
Incubation Time:48 hours
-
Result:Exhibited significant growth inhibition in all three cell lines, with IC50 of 0.8 mM in PC-3 cells, 1.2 mM in TSU-PR1 cells, and 3.1 mM in LNCaP cells.
-
Cell Line:LNCaP cells (human prostate cancer)
-
Concentration:0.5, 2, 5 mM
-
Incubation Time:48 hours
-
Result:Significantly reduced the fraction of LNCaP cells in the S-phase and caused strong accumulation in the G1 phase.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:High-fat diet (HFD)-induced obese mice (C57BL/6)[4]
-
Dosage:2.0 g/kg
-
Administration:Oral gavage (p.o.), 3 times per week, with 48-hour intervals, for 6 weeks
-
Result:Led to lower body weight gain compared to control, improved glucose tolerance, increased insulin sensitivity, and reduced liver triglyceride content.
-
Animal Model:Ceftriaxone (HY-B0712)-induced gut microbiota dysbiosis in C57BL/6 mice
-
Dosage:0.3 g/kg, 3 g/kg
-
Administration:Oral gavage (p.o.), once daily, for 11 days
-
Result:Improved body weight, reduced diarrhea, and less intestinal tissue damage (0.3 g/kg).
Chemical Information
-
CAS No. 60-01-5
-
Appearance Liquid (Density: 1 g/ml)
-
Masse moléculaire 302.36
-
Formule C15H26O6
-
Color Colorless to light yellow
-
SMILES
CCCC(OCC(OC(CCC)=O)COC(CCC)=O)=O
-
Synonyms
Glyceryl tributyrate
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cephalalgia
CGRP-dependent signalling pathways involved in mouse models of GTN- cilostazol- and levcromakalim-induced migraine. [Abstract]2021 Dec;41(14):1413-1426. PMID: 34407650
Solvant et solubilité
DMSO : 100 mg/mL (330.73 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.27 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (277 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. T Gaschott, et al. Tributyrin, a stable and rapidly absorbed prodrug of butyric acid, enhances antiproliferative effects of dihydroxycholecalciferol in human colon cancer cells. J Nutr. 2001 Jun;131(6):1839-43. [Content Brief]
[2]. Claudia P Schröder, et al. Tributyrin-induced differentiation promotes apoptosis of LS 174T colon cancer cells in vitro. Int J Oncol. 2002 Jan;20(1):195-200. [Content Brief]
[3]. Maier S, et al. Tributyrin induces differentiation, growth arrest and apoptosis in androgen-sensitive and androgen-resistant human prostate cancer cell lines. Int J Cancer. 2000 Oct 15;88(2):245-51. [Content Brief]
[4]. Sato FT, et al. Tributyrin Attenuates Metabolic and Inflammatory Changes Associated with Obesity through a GPR109A-Dependent Mechanism. Cells. 2020 Sep 1;9(9):2007. [Content Brief]
[5]. Yang N, et al. Tributyrin alleviates gut microbiota dysbiosis to repair intestinal damage in antibiotic-treated mice. PLoS One. 2023 Jul 31;18(7):e0289364. [Content Brief]
[6]. Vinolo MA, et al. Tributyrin attenuates obesity-associated inflammation and insulin resistance in high-fat-fed mice. Am J Physiol Endocrinol Metab. 2012 Jul 15;303(2):E272-82. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.3073 mL | 16.5366 mL | 33.0732 mL | 82.6829 mL |
| 5 mM | 0.6615 mL | 3.3073 mL | 6.6146 mL | 16.5366 mL | |
| 10 mM | 0.3307 mL | 1.6537 mL | 3.3073 mL | 8.2683 mL | |
| 15 mM | 0.2205 mL | 1.1024 mL | 2.2049 mL | 5.5122 mL | |
| 20 mM | 0.1654 mL | 0.8268 mL | 1.6537 mL | 4.1341 mL | |
| 25 mM | 0.1323 mL | 0.6615 mL | 1.3229 mL | 3.3073 mL | |
| 30 mM | 0.1102 mL | 0.5512 mL | 1.1024 mL | 2.7561 mL | |
| 40 mM | 0.0827 mL | 0.4134 mL | 0.8268 mL | 2.0671 mL | |
| 50 mM | 0.0661 mL | 0.3307 mL | 0.6615 mL | 1.6537 mL | |
| 60 mM | 0.0551 mL | 0.2756 mL | 0.5512 mL | 1.3780 mL | |
| 80 mM | 0.0413 mL | 0.2067 mL | 0.4134 mL | 1.0335 mL | |
| 100 mM | 0.0331 mL | 0.1654 mL | 0.3307 mL | 0.8268 mL |
Tributyrin Related Classifications
HY-W011404 Related Classifications
Powered by Bioz